

Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 Tel: (91-22) 2826 6000 Fax: (91-22) 2826 7337 Website: in.pg.com

August 23, 2022

To, The Corporate Relations Department The BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 **Ref:- Scrip Code:- 500459** To, The Listing Department The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 **Ref:- Scrip Code:- PGHH**

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held on August 23, 2022

We are pleased to inform you that a meeting of the Board of Directors of the Company held today (commence at 12.55 pm and end at 1.40 pm), the Audited Financial Results for the Financial Year ended June 30, 2022 were approved.

We are enclosing herewith the following:

a. Audited Financial Results for the Financial Year ended June 30, 2022, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015;

b. Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company;

c. Press Release;

d. A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results

We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, *inter alia*, have recommended a final dividend of Rs. 65 per Equity Share (Nominal Value of Rs. 10/- each), for the Financial Year ended June 30, 2022. The divided shall be paid between November 15, 2022 to December 13, 2022, on approval of the Members at the 58th Annual General Meeting.

Kindly take the same on record. Thanking you.

For Procter & Gamble Hygiene and Health Care Limited

Ghanashyam Hegde Executive Director and Company Secretary

P&G

Procter & Gamble Hygiene and Health Care Limited CIN : L24239MH1964PLC012971 Registered Office: P&G Pica Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 (91 – 22) 2828 6000 phone (91 – 22) 2828 7337 fax Website: in,pg.com

_	STATEMENT OF AUDITED FINANCIAL RESULTS FOR 1			(11)		(₹ in Lakhs
	Particulars	(1) Three Months	(2) Preceding Three Months	(3) Corresponding Three Months	(4) Year	(5) Previous Year
		Ended	Ended	Ended	Ended	Ended
		30th June 2022	31st Mar 2022	30th June 2021	30th June 2022	30th June 2021
		(Audited)		(Audited)		
		Refer Note 7 below	(Unaudited)	Refer Note 7 below	(Audited)	(Audited)
-		Delow	(Unaudiced)	Detow	(Audited)	(Audrea)
1	income					
1	Sale of products	75 565	88 949	78 558	3 79 245	3 57 024
	Other operating revenues (Refer Note 4)	2 073	8 377	101	10 847	390
2	Revenue from operations	77 638	97 326	78 659	3 90 092	3 57 414
3	Other income	563	603	572	2 4 3 2	3 938
_	Total income (2+3)	78 201	97 929	79 231	3 92 524	3 61 352
4	Expenses					
a)	Cost of raw and packing materials consumed	21 071	34 715	25 293	1 26 034	1 12 839
b)	Purchases of stock-in-trade (Traded goods)	17 368	10 625	1 342	30 545	4 113
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(538)	(766)	(1492)	(650)	(1 022
d)	Employee benefits expense	4 229	5 598	4 188	21 434	20 168
e)	Finance costs	84	682	73	1 119	611
0	Depreciation and amortization expense	1 418	1 312	1 262	5 288	4 766
g)	Impairment iosses (Refer Note 5)					764
h)	Advertising & sales promotion expenses	9 692	11 234	19 4 13	47 124	52 248
11	Other expenses	19 107	19 4 19	22 427	82 616	79 876
_	Total expenses	72 431	82 819	72 506	3 13 510	2 74 363
5	Profit before tax (2+3-4)	5 770	15 110	6 725	79 014	86 989
6	Tax expense					
a)	Current tax	1518	4 613	1 786	21 950	22 873
b)	Deferred tax	(61)	(499)	(90)	(1282)	(889
c)	Prior year tax adjustments	- 60	711	131	771	174
	al - Land Care, and Manaka Jacob - Company Care and	1 515	4 825	1 827	21 439	21 810
7	Profit for the period (5-6)	4 255	10 285	4 898	57 575	65 179
8	Other comprehensive income					
	Items that will not be reclassified to profit or loss;					
	Re- measurement of the defined benefit plans	82	804	(382)	729	179
	Income tax effect on above	(20)	(202)	96	(183)	(45
	Total other comprehensive income for the period	62	602	(286)	546	134
9	Total comprehensive income for the period (7+8)	4 317	10 887	4 612	58 121	65 313
10	Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 2 4 6	3 246
11	Other Equity				70 511	68 181
12	Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :					
a)	Basic	13.11	31.68	15,09	177.37	200.79
b)	Diluted	13.11	31.68	15.09	177.37	200.79
See	accompanying notes to the financial results					

Notes: 1 Statement of Assets and Liabilities

	As at 30 th June 2022	As at 30 th June 2021
Particulars	(Audited)	(Audited)
Assets Non-current assets		
	10.000	10.00
Property, plant and equipment	16 368	18 38
Capital work-in-progress	4 388	3 75
Financial assets		
(i) Loans	2 842	2 91
(ii) Other financial assets	924	88
Deferred tax assets (Net)	5 188	3 80
Non-current tax assets (Net)	16 861	15 12
Other non-current assets	8 177	6 67
Total non-current assets	54 748	51 53
Current assets		
Inventories	23 402	24 93
Financial assets		
(I) Trade receivables	19 075	14 23
(ii) Cash and cash equivalents	62 498	64 76
(iii) Bank balances other than (ii) above	1 427	1 25
(iv) Loans	573	57
(v) Other financial assets	2 030	2 52
Other current assets	4 371	3 45
	1 13 376	1 11 73
Non current assets held for sale		111.70
Total current assets	1 13 376	1 11 73
Total assets	1 68 124	1 63 27
I OTMI MARQUO	100 124	103.21
Equity and flabilities		
Equity		
Equity share capital a	3 246	3 24
Other equity	70 511	68 18
Total equity	70 511	71 42
l otal equity	13 (3)	/1 42
Non-current liabilities		
Financial liabilities		
(i) Lease liabilities	194	18
Provisions	8 389	8 280
Fotal non-current liabilities	8 583	8 298
Surrent flabilities		
Financial liabilities		
(i) Lease liabilities	316	329
(ii) Trade payabies		
Total outstanding dues of micro enterprises and small enterprises	2 178	1 255
Total outstanding dues of creditors other than micro enterprises and small enterprises	75 665	74 155
(ii) Other financial liabilities	2 548	3 270
Provisions	840	500
Current tax liabilities (Net)	515	705
Other current liabilities	3 722	3 332
other current liabilities	85 784	
otal current liabilities Total liabilities	94 367	83 546
		91 844
otal equity and liabilities	1 58 124	1 63 271





Particulars	Year Ended 30 th June 2022 (Audited)	Year Ended 30 th June 2021 (Audited)
A. Cash Flows from Operating Activities		4
Profit before tax	79 014	86 989
Adjustments for:	10014	00 000
Depreciation and amortization expense	5 288	4 765
Loss on disposal of property, plant and equipment	176	185
Finance costs	776	593
Allowance for doubtful receivables (Net of recovery)	41	(112
Interest income	(2 318)	(3 0 97
Impairment losses	(= ;	764
Net foreign exchange (gain) / loss	(83)	(140
Expense recognised in respect of equity settled share based payments	1 015	695
Operating profit before working capital changes	83 909	90 643
Working capital adjustments		
(increase) / decrease in trade and other receivables	(4 886)	2 5 3 8
Decrease in financial assets	554	97
Decrease / (increase) in inventories	1 528	(4 425
(Increase) in other assets	(2 423)	(1 326
Increase in trade and other pavables	2 911	23 542
Increase in provisions	653	583
Cash generated from operations	82 246	1 11 652
Income taxes paid	24 936)	(25 340
Net cash generated from operating activities	57 310	86 312
B. Cash Flows from Investing Activities		
interest received	2 288	3 056
Payment to acquire property, plant and equipment	(4 980)	(3 160)
Proceeds from sale of property, plant and equipment	7	14
Changes in earmarked balances		784
Net cash (used in) / generated from investing activities	(2 685)	694
C. Cash Flows from Financing Activities		
Dividend and dividend tax paid	(56 806)	(1 10 367)
Principal payment of lease liabilities	163	(157)
Interest paid on lease liabilities	(6)	(18)
interest paid other than on lease liabilities	(245)	(101)
Net cash (used in) financing activities	(56 894)	(1 10 643)
Net increase / (decrease) in cash and cash equivalents	(2 269)	(23 637)
Cash and cash equivalents at the beginning of the year	64 767	88 404
Cash and cash equivalents at the end of the year	62 498	64 767

3 The above audited financial results for the quarter and year ended June 30, 2022 have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at their Meeting held on August 23, 2022.

Meeting held on August 23, 2022. 4 Other operating revenues for the current quarter and the year ended June 30, 2022 includes an amount of ₹ 1 B11 lakhs and ₹ 10 110 lakhs respectively on account of sale of materials consequent to the change in the business model from toller to contract manufacturing. 5 During the previous year ended June 30, 2021, Non-Current Assets Held for Sale were fully impaired on a conservative basis since the Company was unable to dispose off the said assets. Consequently, an impairment loss amounting to ₹ 704 klakhs was recognized in the Statament of Profit and Loss for the previous year. These assets continue to be classified as held for sale as at June 30, 2022, since the management intends to dispose off these assets and is actively pursuing the said matter.

6 The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.

The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year. The Board of Directors at its meeting held on August 23, 2022 have recommended a payment of final dividend of ₹ 65 per equity share of face value of ₹ 10 each for the financial year ended June 30. 2022 resulting in a dividend payout of ₹ 10 each for the financial year ended June 30. 2022 7 8

9 Previous period figures have been regrouped / reclassified wherever necessary.

Place: Mumbai Date: August 23, 2022



For and on behalf of the Board of Directors of Procter & Gamble Hygiene and Health Care Limited

[ei a Ð LV Vaidyanathan

Managing Director



KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly and Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED

Report on the Audit of the Financial Results

Opinion

We have audited the accompanying quarterly and annual Financial Results of **PROCTER** & **GAMBLE HYGIENE AND HEALTH CARE LIMITED**) (the Company) for the quarter ended June 30, 2022 and the year to date results for the period from July 1, 2021 to June 30, 2022, together with the notes thereon ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), duly initialled by us for identification.

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 (the Act), read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended June 30, 2022 as well as the year to date results for the period from July 1, 2021 to June 30, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Financial Results

These quarterly as well as the year to date financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate

internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

Attention is drawn to the fact that the figures for the quarters ended June 30, as reported in these financial results are the balancing figures between audited figures in respect of the full financial years ended June 30 and the published year to date figures up to the end of the third quarter of the relevant financial years. The figures up to the end of the third quarter have only been reviewed and not subjected to audit.

For KALYANIWALLA & MISTRY LLP CHARTERED ACCOUNTANTS Firm Regn. No.: 104607W / W100166



Mumbai: August 23, 2022



Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai - 400099 Tel: (91-22) 2826 6000 Fax: (91-22) 2826 7337 Website: in.pg.com

Procter & Gamble Hygiene and Health Care Ltd. announces fiscal and fourth-quarter results

Sales up 9% for the fiscal ended June 30, 2022

Mumbai, August 23, 2022: Procter & Gamble Hygiene and Health Care Ltd. today announced its financial results for the fiscal and quarter ended June 30, 2022. Despite unprecedented headwinds from macroeconomic challenges and softening consumption trends, the Company continued to grow and delivered a resilient performance in the fiscal with sales of ₹3,901 crore, up 9% versus year ago, behind the proven superiority strategy and strong brand fundamentals. Profit After Tax (PAT) was ₹576 crore, down 12% versus year ago, largely behind commodities inflation which was significantly countered by cost productivity and pricing in the current year. Compared to the fiscal two years ago, the Company's sales are up 30% and Profit After Tax (PAT) is up 33%.

For the quarter ended June 30, 2022, the company delivered sales of ₹776 crore, down 1% versus year ago. Profit After Tax (PAT) was ₹43 crore, down 13% versus year ago largely behind commodity cost inflation. For the quarter, both feminine care and healthcare businesses continue to grow and maintain category leadership.

LV Vaidyanathan, Managing Director, Procter & Gamble Hygiene and Health Care Ltd. said, "The operating environment continues to be marked by unprecedented headwinds and commodity fluctuations. Despite these challenges, we remain resilient, agile, and committed to serve Indian consumers, delivering sequential sales growth this year. The execution of our integrated strategies of a strong portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure, has empowered us to deliver these consistent results. Our strategy is fueled by balancing innovation and industry-leading practices, while driving productivity in everything we do." He further added, "While the unprecedented market challenges and uncertainties remain in the near-term, we will continue to stay focused on our strategy of driving superiority and productivity and enabled by the strength of our organization and culture, to deliver balanced growth and value creation."

Our feminine care and healthcare brands, Whisper and Vicks, continue to grow behind a strong product portfolio, superior consumer communication and a continuous stream of product innovations like Whisper Choice Nights, Vicks Roll-On Inhaler, Vicks Xtra Strong and Vicks Tulsi Ginger Cough Syrup.

Our brands also continued to step up as a force for good. Whisper launched - 'The Missing Chapter' (<u>https://www.youtube.com/watch?v=HyezvRuAc7Y</u>), as the next edition of #KeepGirlsInSchool initiative, to fight period taboos and advocate the inclusion of period education in the mandatory school curriculum to prevent girls from dropping out of schools. For this, Whisper also won multiple awards at the coveted Cannes Lions International Festival of Creativity 2022, including India's first 'Grand Prix' in the 'Sustainable Development Goals' category. Whisper continues to raise awareness about menstrual hygiene education through 'Whisper Menstrual Health & Hygiene Program', actively supporting 50,000+ schools and reaching about 1 crore adolescent girls this fiscal.



Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai - 400099 Tel: (91-22) 2826 6000 Fax: (91-22) 2826 7337 Website: in.pg.com

The Company continues to aspire to create positive impact across each area of Citizenship– Community Impact, Equality & Inclusion, and Environmental Sustainability. Through its flagship CSR program, P&G Shiksha, the P&G group in India has supported over 2500 schools that will impact more than 23 lakh children. Over the years, P&G Shiksha has evolved into a 360-degree educational intervention addressing three critical barriers to achieving universal education – access to education infrastructure, gender inequality in access to education and gap in learning.

The directors have recommended a final dividend of ₹ 65 per Equity Share for the Financial Year ended June 30, 2022, subject to the approval of Shareholders of the company at the ensuing 58th Annual General Meeting.

About Procter & Gamble Hygiene and Health Care Limited

Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) is one of India's fastest growing FMCG companies that has in its portfolio WHISPER – India's leading Feminine Hygiene brand, and VICKS – India's No. 1 Health Care brand and Old Spice. The company has carved a reputation for delivering high quality, value-added products to meet the needs of consumers. PGHHCL is committed to making every day in the lives of Indian consumers better through superior value propositions. Please visit in.pg.com for the latest news.

For details contact: Madison Public Relations:

Malika Bhavnani +91 9820496099; malika.bhavnani@madisonpr.in



Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 Tel: (91-22) 2826 6000 Fax: (91-22) 2826 7337 Website: in.pg.com

August 23, 2022

To, The Corporate Relations Department The BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 **Ref:- Scrip Code:- 500459** To, The Listing Department The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 **Ref:- Scrip Code:- PGHH**

Dear Sir/Madam,

Sub: Declaration with respect to Audit Report with unmodified opinion to the Audited Financial Results for the Financial Year ended June 30, 2022

We hereby declare that Audited Financial Results for the Financial Year ended June 30, 2022 which have been approved by the Board of Directors of the Company at meeting held today, i.e., August 23, 2022, the Statutory Auditors, Kalyaniwalla & Mistry LLP have not expressed any modified opinion(s) in their Audit Report.

The above declaration is made pursuant to Regulation 33 (3) (d) of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Yours faithfully,

For Procter & Gamble Hygiene and Health Care Limited

Ghanashyam Hegde Company Secretary